LPCNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Lipocine Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$1.53−0.03 (-1.92%)
Close on Oct 19, 2026
- Market cap
- $12.57M
- P/E (TTM)
- –
- Dividend yield
- –
Lipocine statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Lipocine | Industry median |
|---|---|---|
| Market Cap | $12.61M | $164.85M |
| Enterprise Value | -$10.65M | $87.06M |
| PS Ratio | 8.04 | 3.60 |
| PB Ratio | 0.58 | 2.03 |
| P/TBV Ratio | 0.58 | 2.31 |
Enterprise value
| Measure | Lipocine | Industry median |
|---|---|---|
| EV / Sales | -6.79 | 2.43 |
Income (trailing twelve months)
| Measure | Lipocine | Industry median |
|---|---|---|
| Revenue | $1.57M | $57.94M |
| Operating Income | -$12.57M | -$21.44M |
| Pretax Income | -$11.85M | -$14.45M |
| Net Income | -$11.85M | -$22.46M |
| EBITDA | -$12.51M | -$16.91M |
| EPS (Diluted) | -$1.80 | -$0.83 |
Margins
| Measure | Lipocine | Industry median |
|---|---|---|
| Operating Margin | -800.8% | -44.5% |
| Pretax Margin | -755.1% | -13.0% |
| Profit Margin | -755.1% | -39.2% |
| EBITDA Margin | -797.1% | -31.3% |
Returns
| Measure | Lipocine | Industry median |
|---|---|---|
| Return on Equity (ROE) | -60.9% | -53.1% |
| Return on Assets (ROA) | -55.9% | -41.0% |
| Return on Capital Employed (ROCE) | -57.7% | -37.8% |
Growth
| Measure | Lipocine | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -62.7% | 6.01% |
| Revenue Growth (3Y CAGR) | 58.1% | 2.25% |
Balance sheet
| Measure | Lipocine | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $23.27M | $62.42M |
| Net Cash (Debt) | $23.27M | $15.68M |
| Net Cash Per Share | $2.82 | $0.66 |
| Equity (Book Value) | $21.77M | $48.79M |
| Book Value Per Share | $2.64 | $1.36 |
| Tangible Book Value | $21.77M | $23.06M |
| Working Capital | $21.67M | $75.77M |
Financial position
| Measure | Lipocine | Industry median |
|---|---|---|
| Current Ratio | 11.48 | 3.30 |
| Quick Ratio | 11.25 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Lipocine | Industry median |
|---|---|---|
| Operating Cash Flow | -$11.19M | -$12.35M |
Efficiency
| Measure | Lipocine | Industry median |
|---|---|---|
| Asset Turnover | 0.07 | 0.38 |
| Revenue Per Employee | $112.10K | $398.96K |
| Profits Per Employee | -$846.53K | -$703.34K |
| Employee Count | 14 | 74 |
Dividends and yields
| Measure | Lipocine | Industry median |
|---|---|---|
| Earnings Yield | -94.0% | -22.7% |
| Buyback Yield | -129.0% | -0.73% |
| Shareholder Yield | -129.0% | 0.00% |
Shares
| Measure | Lipocine | Industry median |
|---|---|---|
| Shares Outstanding | 8,244,250 | 58,179,650 |
| Shares Change (YoY) | 24.9% | 11.1% |
| Shares Change (QoQ) | 10.3% | 0.54% |
| Float | 7,575,870 | 49,173,100 |
| Shares Held by Insiders | 8.11% | 11.6% |
| Shares Held by Institutions | 36.2% | 59.4% |
Scores
| Measure | Lipocine | Industry median |
|---|---|---|
| Altman Z-Score | -9.59 | -0.24 |
| Piotroski F-Score | 1 | 4 |
Calculated by StockData from Lipocine's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.